Overview
Legal name
GENDIUS LIMITED
Region
Unknown
Registered address
Unknown
Insolvency history
No
Company
Active
LTD
Company profile
Gendius Limited
Home - Gendius
Experts in health data Redefining personalised care with innovative solutions using rich metabolic data, enabling healthcare teams to improve patient outcomes. Our partners Creating data driven solutions for good User ExperienceWe include our users throughout each project, ensuring our solutions are optimised specifically to their needs. Health DataUtilising our expertise in metabolic data and methodologies to
CRN
08525197
Founded
2013
Age
12
Corporate ownership
Updated 06 Jun 2026 16:52
11 levels
2 ultimate controllers
1
Company
Active
LTD
Gendius Limited
CRN 08525197
2
Direct controller
Active
LTD
Catapult Venture Managers Limited
CRN 03818199
3
Intermediate controller
Active
LTD
Catapult Ultimate Holdings Limited
CRN 08565190
4
Intermediate controller
Active
LTD
BW Sipp Trustees Limited
CRN 03011174
5
Ultimate controller
Active
LTD
Slingshot Buyout Limited
CRN 08542007
6
Intermediate controller
Active
LLP
Barnett Waddingham LLP
CRN OC307678
7
Intermediate controller
Active
LTD
Howden UK&I Holdings Limited
CRN 12875660
8
Intermediate controller
Active
LTD
Howden Broking Group Limited
CRN 06249799
9
Intermediate controller
Active
LTD
Hyperion Development UK Limited
CRN 09348999
10
Intermediate controller
Active
LTD
HGH Midco 3 Limited
CRN 13646017
11
Intermediate controller
Active
LTD
Hig Finance 2 Limited
CRN 10842605
12
Intermediate controller
Active
LTD
HGH Finance Limited
CRN 13645436
13
Intermediate controller
Active
LTD
HGH Midco 2 Limited
CRN 13644440
14
Intermediate controller
Active
LTD
HGH Midco 1 Limited
CRN 13642978
15
Ultimate controller
Active
LTD
Howden Group Holdings Limited
CRN 02937398
Company events
Reference milestones and recent Companies House filing stream events.
1 event
13 May
2013
Incorporated
InceptionCompany registered at Companies House
Public funding
2 awards
First funded
2017
Funded years
2017, 2023
Age at first award
3 years
Projects
2023
Investment Accelerator
GM Advanced Diagnostics Accelerator
1 Apr 2023 to 31 Mar 2025
Awarded
£167,845
Total cost £239,778
no public description
2017
Collaborative R&D
Lead participant
Intellin: A smart platform to reduce the reoccurrence of diabetic foot ulcers
1 May 2017 to 30 Apr 2020
Awarded
£196,979
Total cost £281,398
Diabetic Foot Ulcers (DFUs) are a major worldwide issue, occurring in 15% of diabetes sufferers and 56% of these patients die within 5 years of the first occurrence. The recurrence rate is approximately 50% per annum with current methods and treatment requiring a multidisciplinary assessment (including diabetes specialists, surgeons and podiatrists). Ther...
Product types
Collaborative R&D
Investment Accelerator